Immunomodulatory effects of antimicrobial agents. Part II: Antiparasitic and antifungal agents

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 3, 2012, Pages 341-357

  Labro, Marie Thérèse ^a  

^a INSERM   (France)

Author keywords

antibacterial agents; antiviral agents; immune system; immunomodulation; infections

Indexed keywords

ALLOPURINOL; AMODIAQUINE; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; ARTEMISININ DERIVATIVE; BENZNIDAZOLE; CHLOROQUINE; DEHYDROEMETINE; DIETHYLCARBAMAZINE; DIHYDROARTEMISININ; EMETINE; FURAZOLIDONE; HYDROXYCHLOROQUINE; MEBENDAZOLE; MEFLOQUINE; MELARSOPROL; MEPACRINE; METRONIDAZOLE; MILTEFOSINE; NIFURTIMOX; OLTIPRAZ; PENTAMIDINE; PENTAMIDINE ISETHIONATE; POTASSIUM IODIDE; PROGUANIL; PYRANTEL; PYRIMETHAMINE; QUININE; SURAMIN; UNINDEXED DRUG;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADVANCED CANCER; AGRANULOCYTOSIS; ALLERGIC URTICARIA; ALLERGIC VASCULITIS; ANGIONEUROTIC EDEMA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRALGIA; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CORONAVIRUS INFECTION; CROHN DISEASE; DISEASE TRANSMISSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRESS SYNDROME; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; ERYTHEMA MULTIFORME; EYE ALLERGY; FEVER; FILARIASIS; GRANULOMATOUS HEPATITIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HOST RESISTANCE; HUMAN; HYPOTENSION; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; INFECTION CONTROL; KIDNEY FAILURE; LEUKOPENIA; LYMPHADENOPATHY; MACULOPAPULAR RASH; MEGALOBLASTIC ANEMIA; METASTASIS; MYCOSIS; NECROTIZING ARTERITIS; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PANCYTOPENIA; PRURITUS; PUBLIC HEALTH PROBLEM; RASH; REVIEW; RHEUMATIC DISEASE; SKIN ALLERGY; SKIN DEFECT; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TACHYCARDIA; TACHYPNEA; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; VIRUS INFECTION;

ANIMALS; ANTIFUNGAL AGENTS; ANTIPARASITIC AGENTS; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; MICE; MYCOSES; PARASITIC DISEASES;

EID: 84858220414     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.12.10     Document Type: Review

References (107)

1. Cox FE. History of human parasitic diseases. Infect. Dis. Clin. North Am. 18(2), 171-188 (2004). (Pubitemid 38622398)
2. Morrissette NS, Ajioka JW. The early years of Toxoplasma research: what's past is prologue. Int. J. Parasitol. 39(8), 865-869 (2009).
3. Steverding D. The development of drugs for treatment of sleeping sickness: a historical review. Parasit. Vectors 3(1), 15 (2010).
4. Kappadoga S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clin. Proc. 86, 561-583 (2011).
5. Ioset JR, Chang S. Drugs for neglected diseases initiative model of drug development for neglected diseases: current status and future challenges. Future Med. Chem. 3(11), 1361-1371 (2011).
6. Musa AM, Younis B, Fadlalla A et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label,dose-finding study. PLoS Negl. Trop. Dis. 4(10), e855 (2010).
7. Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G. Geographicalvariation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl. Trop. Dis. 24(10), e709 (2010).
8. Lawton P, Sarciron ME, Petavy AF. Chemotherapeutic targets for antiparasitic therapy. Drugs Fut. 31(9), 793-809 (2006). (Pubitemid 44875211)
9. Crowther GJ, Shanmugam D, Carmona SJ et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl. Trop. Dis. 4(8), e804 (2010).
10. Zucca M, Savoia D. Current developments in the therapy of protozoan infections. Open Med. Chem. J. 5, 4-10 (2011).
11. Bergquist R, Lustigman S. Control of important helminthic infections vaccine development as part of the solution. Adv. Parasitol. 73, 297-326 (2010).
12. Carvalho JA, Rodgers J, Atouguia J, Prazeres DM, Monteiro GA. DNA vaccines: a rational design against parasitic diseases. Expert Rev. Vaccines 9(2), 175-191 (2010).
13. Bethony JM, Loukas A, Hotez PJ, Knox DP. Vaccines against blood-feeding nematodes of humans and livestock. Parasitology 133(Suppl.) S63-S79 (2006). (Pubitemid 46208031)
14. Agnandji ST, Lell B, Soulanoudjingar SS et al. The RTS,S clinical trials partnership. First results of Phase III trial of RTS,S/AS01 malaria vaccine in African children N. Engl. J. Med. 365(20), 1863-1875 (2011).
15. Malaria Eradication Research Agenda (malERA). Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med. 8(1), e1000398 (2011).
16. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol. 21(3), 143-149 (2005). (Pubitemid 40269779)
17. Da'dara AA, Li YS, Xiong T et al. DNA-based vaccines protect against zoonotic schistosomiasis in water buffalo. Vaccine 26(29-30), 3617-3625 (2008).
18. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin. Microbiol. Rev. 21(1), 225-242 (2008). (Pubitemid 351160017)
19. Okwor I, Uzonna JE. Immunotherapy as a strategy for treatment of leishmaniasis: a review of the literature. Immunotherapy 1(5), 765-776 (2009).
20. Musa AM, Noazin S, Khalil EAG, Modabber F. Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration. Trans. R. Soc. Trop. Med. Hyg. 104(1), 1-2 (2010).
21. Holden-Dye L, Walker, RJ. Anthelmintic drugs. WormBook 2, 1-13 (2007).
22. Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen. Pharmacol. 28(2), 273-299 (1997) (Pubitemid 27016138)
23. Denton H, McGregor JC, Coombs GH. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J. 381(Pt 2), 405-412 (2004). (Pubitemid 38969684)
24. Liu LX, Weller PF. Antiparasitic drugs. N. Engl. J. Med. 334(18), 1178-1184 (1996).
25. Astelbauer F, Walochnik J. Antiprotozoal compounds: state of the art and new developments. Int. J. Antimicrob. Agents 50(7), 2420-2427 (2011).
26. Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans. R. Soc. Trop. Med. Hyg. 103(7), 653-660 (2009)
27. Labro MT. Immunomodulatory effects of antimicrobial agents. Part I: antibacterial and antiviral agents. Expert Rev. Anti Infect. Ther. 10(3), 319-340 (2012).
28. Pinazo MJ, Muoz J, Posada E et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob. Agents Chemother. 54(11), 4896-4899 (2010).
29. Altcheh J Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 127(1) e212-e218 (2011).
30. Hung, SI, Chung WH, Liou LB et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl Acad.Sci. USA 102(11), 4134-4139 (2005).
31. Taylor WR, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 27(1), 25-61 (2004). (Pubitemid 38186936)
32. Ugburo AO, Ilombu CA, Temiye EO, Fadeyibi IO, Akinolai OI. Severe idiosyncratic drug reaction (Lyells syndrome) after ingesting dihydroartemisinin. Niger. J. Clin. Pract. 12(2), 224-227 (2009).
33. Luong MS, Bessis D, Raison-Peyron N, Pinzani V, Guilhou JJ, Guillot B. Severe mucocutaneous necrotizing vasculitis associated with the combination of chloroquine and proguanil. Acta. Derm. Venereol. 83(2), 141 (2003). (Pubitemid 36433963)
34. Gasasira AF, Kamya MR, Achan J et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin. Infect. Dis. 46(7), 985-991 (2008). (Pubitemid 351589861)
35. Bowman ZS, Morrow JD, Jollow DJ, McMillan DC. Primaquine-induced hemolytic anemia: role of membrane lipid peroxidation and cytoskeletal protein alterations in the hemotoxicity of 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 314(2), 838-845 (2005). (Pubitemid 41043869)
36. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic chagas disease. Clin. Infect. Dis. 51(10), e69-e75 (2010).
37. Just N, Carpentier O, Brzezinki C, Steenhouwer F, Staumont-Sallé D. Severe hypersensitivity reaction as acute eosinophilic pneumonia and skin eruption induced by proguanil. Eur. Respir. J. 37(6), 1526-1528 (2011).
38. Kowalski TJ, Henry MJ, Zlabek JA. Furazolidone-induced pulmonary hypersensitivity. Ann. Pharmacother. 39(2), 377-379 (2005). (Pubitemid 40165234)
39. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, Wozniacka A. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus 19(6), 683-688 (2010).
40. Shakir L, Hussain M, Javeed A, Ashraf M, Riaz A. Artemisinins and immune system. Eur. J. Pharmacol. 668(1-2), 6-14 (2011).
41. Prato M, Gallo V, Giribaldi G, Aldieri E, Arese P. Role of the NF-kB transcription pathway in the haemozoin-and 15-HETE-mediated activation of matrix metalloproteinase-9 in human adherent monocytes. Cell Microbiol. 12(12), 1780-1791 (2010).
42. Wang J, Zhou H, Zheng J et al. The antimalarial artemisinin synergizes with antibiotics to protect against lethal live Escherichia coli challenge by decreasing proinflammatory cytokine release. Antimicrob. Agents Chemother. 50, 2420-2427 (2006). (Pubitemid 43993181)
43. Zhao M, Xue DB, Zheng B, Zhang WH, Pan SH, Sun B. Induction of apoptosis by artemisinin relieving the severity of inflammation in caerulein-induced acute pancreatitis. World J. Gastroenterol. 13, 5612-5617 (2007). (Pubitemid 350031482)
44. Cuzzocrea SS, Paola FD, Mirshafiey RA. Artemether: a new therapeutic strategy in experimental rheumatoid arthritis. Immunopharmacol. Immunotoxicol. 27, 615-630 (2005).
45. Noori S, Hassan, ZM, Taghikhani M, Rezaei B, Habibi Z. Dihydroartemisinin can inhibit calmodulin, calmodulin-dependent phosphodiesterase activity and stimulate cellular immune responses. Int. Immunopharmacol. 10, 213-217 (2010).
46. Al-Krawi EA, Al-Hashimi AH. Study of aerobic granulocyte functional activity in the presence of a radiosensitizer (metronidazole). East Mediterr. Health J. 15(1), 224-229 (2009).
47. Bamias G, Marini M, Moskaluk CA et al. Down-regulation of intestinal lymphocyte activation and Th1 cytokineproduction by antibiotic therapy in a murine model of Crohn's disease. J. Immunol. 169(9), 5308-5314 (2002). (Pubitemid 35217204)
48. Saha P, Mukhopadhyay D, Chatterjee M. Immunomodulation by chemotherapeutic agents against leishmaniasis. Int. Immunopharmacol. 11(11), 1668-1679 (2011).
49. Mookerjee Basu J, Mookerjee A, Sen P et al. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob. Agents Chemother. 50(5), 1788-1797 (2006).
50. Wadhone P, Maiti M, Agarwal R, Kamat V, Martin S, Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol. 182(11), 7146-7154 (2009).
51. Ansari NA, Ramesh V, Salotra P. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 102(11), 1160-1162 (2008).
52. Mukhopadhyay D, Das NK, Roy S, Kundu S, Barbhuiya JN, Chatterjee M. Miltefosine effectively modulates the cytokine milieu in Indian post kala-azar dermal leishmaniasis. J. Infect. Dis. 204(9), 1427-1436 (2011).
53. Griewank K, Gazeau C, Eichhorn A, von Stebut E. Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions. Antimicrob. Agents Chemother. 54(2), 652-659 (2010).
54. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin. Rev. Allergy Immunol. doi:10.1007/s12016-010-8243 (2011) (Epub ahead of print).
55. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann. Rheum. Dis. 69(1), 20-28 (2010).
56. Keyaerts E, Li S, Vijgen L et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob. Agents Chemother. 53(8), 3416-3421 (2009).
57. Paton NI, Lee L, Xu Y et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect. Dis. 11, 677-684 (2011).
58. Hou LF, He SJ, Wang JX et al. SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. Int. Immunopharmacol. 9, 1509-1517 (2009).
59. Yang ZS, Zhou WL, Sui Y et al. Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-dihydroartemisininoxy] phen(ox)yl aliphatic acids and esters. J. Med. Chem. 48, 4608-4617 (2005). (Pubitemid 40993421)
60. He RR, Zhou HJ. Progress in research on the anti-tumor effect of artesunate. Chin. J. Integr. Med. 14(4), 312-316 (2008).
61. Lawrance I. Novel topical therapies for distal colitis. World J. Gastrointest. Pharmacol. Ther. 1(5), 87-93 (2010).
62. Ng SC, Chan FKL, Sung JJ. The role of non-biological drugs in refractory IBD Aliment. Pharmacol. Ther. 33(4), 417-427 (2011).
63. Ruggeri BA, Robinson C, Angeles T, Wilkinson J 4th, Clapper ML. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin. Cancer Res. 8(1), 267-274 (2002). (Pubitemid 34101487)
64. Ainsworth GC. Introduction to the History of Medical and Veterinary Mycology. Cambridge University Press, Cambridge, UK (2002).
65. Ainsworth GN. Introduction to the History of Mycology. Cambridge University Press, Cambridge, UK (1976).
66. Warnock DW. Fungal diseases: an evolving public health challenge. Med. Mycol. 44(8), 697-705 (2006). (Pubitemid 44824447)
67. Lattif AA Swindell K. History of antifungals. In: Antifungal Therapy. Ghannoum MA, Perfect JR (Eds). Informa Healthcare, NY, USA 1-10 (2010).
68. Andriole VT. Current and future antifungal therapy: new targets for antifungal therapy. Int. J .Antimicrob .Agents 16(3), 317-321 (2000).
69. Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of Modern Antifungals. Clin. Infect. Dis. 47, 226-235 (2008). (Pubitemid 351952889)
70. Chapman SW, Sullivan DC, Cleary JD. In search of the holy grail of antifungal therapy. Trans. Am. Clin. Climatol. Assoc. 119, 197-215 (2008).
71. Mathew BP, Nath M. Recent approaches to antifungal therapy for invasive mycoses. Chem. Med. Chem. 4(3), 310-323 (2009).
72. Hamad M. Antifungal immunotherapy and immunomodulation: a double-hitter approach to deal with invasive fungal infections. Scand. J. Immunol. 67(6), 533-543 (2008). (Pubitemid 351677410)
73. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5(1), 13-28 (2007). (Pubitemid 44942300)
74. van de Sande WW, Lo-Ten-Foe JR, van Belkum A, Netea MG, Kullberg BJ, Vonk AG. Mycoviruses: future therapeutic agents of invasive fungal infections in humans? Eur. J. Clin. Microbiol. Infect. Dis. 29(7), 755-763 (2010).
75. Villar CC, Dongari-Bagtzoglou A. Immune defence mechanisms and immunoenhancement strategies in oropharyngeal candidiasis. Expert Rev. Mol. Med. 13, 10 (2008).
76. Rice PJ, Adams EL, Ozment-Skelton T et al. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J. Pharmacol. Exp. Ther. 314(3), 1079-1086 (2005). (Pubitemid 41205971)
77. Heitman J. Cell biology. A fungal achilles' heel. Science 309(5744), 2175-2176 (2005). (Pubitemid 41396059)
78. Pachl J, Svoboda P, Jacobs F et al. A randomized, blinded, multicentertrial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42, 1404-1413 (2006).
79. Martinez LR, Bryan RA, Apostolidis C, Morgenstern A, Casadevall A, Dadachova E. Antibody-guided alpha radiation effectively damages fungal biofilms. Antimicrob. Agents Chemother. 50, 2132-2136 (2006). (Pubitemid 43807535)
80. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch. Med. Res. 37(7), 899-902 (2006). (Pubitemid 44333152)
81. Pillans PI, Boyd IW. Toenails and agranulocytosis. Intern. Med. J. 37(8), 572-575 (2007). (Pubitemid 47084176)
82. Kubiak DW, Bryar JM, McDonnell AM et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin. Ther. 32(4), 637-648 (2010).
83. Cleary JD, Schwartz M, Rogers PD, de Mestral J, Chapman SW. Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 3(8), 966-973 (2003). (Pubitemid 36903996)
84. Gigliotti F, Shenep JL, Lott L, Thornton D. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. J. Infect. Dis. 156, 784-789 (1987). (Pubitemid 17157429)
85. Meletiadis J, Chanock S, Walsh TJ. Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents. Pharmacogenomics 9(5), 561-584 (2008). (Pubitemid 351803917)
86. Lamaris GA, Lewis RE, Chamilos G et al. Caspofungin-mediated b glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198, 186-192 (2008). (Pubitemid 352019283)
87. Stevens DA. A possible mechanism for synergy between antifungal therapy and immune defense. J. Infect. Dis. 198, 159-162 (2008). (Pubitemid 352019279)
88. Choi JH, Kwon EY, Park CM et al. Immunomodulatory effects of antifungal agents on the response of human monocytic cells to Aspergillus fumigatus conidia. Med. Mycol. 48, 704-709 (2010).
89. Charvalos E, Tzatzarakis MN, Van Bambeke F et al. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J. Antimicrob. Chemother. 57(2), 236-244 (2006). (Pubitemid 43160164)
90. Simitsopoulou M, Roilides E, Dotis J et al. Differential expression ofcytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B. Antimicrob. Agents Chemother. 49, 1397-1403 (2005). (Pubitemid 40463368)
91. Sau K, Mambula SS, Latz E et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor-and CD14-dependent mechanism. J. Biol. Chem. 278, 37561-37568 (2003). (Pubitemid 37175278)
92. Razonable RR, Henault M, Lee LN et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of Toll-like receptor 1 and 2. Antimicrob. Agents Chemother. 49, 1617-1621 (2005). (Pubitemid 40463404)
93. Simitsopoulou M, Roilides E, Likartsis C et al. Expression of immunomodulatory genes in human monocytes induced by voriconazole in the presence of Aspergillus fumigatus. Antimicrob. Agents Chemother. 51(3), 1048-1054 (2007). (Pubitemid 46355294)
94. Simitsopoulou M, Roilides E, Paliogianni F et al. Immunomodulatory effects of voriconazole on monocytes challenged with Aspergillus fumigatus: differential role of Toll-like receptors. Antimicrob. Agents Chemother. 52, 3301-3306 (2008).
95. Kinoshita K, Iwasaki H, Uzui H, Ueda T. Candin family antifungal agent micafungin (FK463) modulates the infl ammatory cytokine production stimulated by lipopolysaccharide in THP-1 cells. Transl. Res. 148, 207-213 (2006). (Pubitemid 44416363)
96. Subissi A, Monti D, Togni G, Mailland F. Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent. Drugs 70(16), 2133-2152 (2010).
97. Liebel F, Lyte P, Garay M, Babad J, Southall MD. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Arch. Dermatol. Res. 298(4), 191-199 (2006). (Pubitemid 44325631)
98. Sur R, Babad JM, Garay M, Liebel FT, Southall MD. Anti-inflammatory activity of sertaconazole nitrate is mediated via activation of a p38-COX-2-PGE2 pathway. J. Invest. Dermatol. 128(2), 336-344 (2008).
99. Weir SJ, Patton L, Castle K, Rajewski L, Kasper J, Schimmer AD. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy. J. Clin. Pharm. Ther. 36(2), 128-134 (2011).
100. Zhou H, Shen T, Luo Y et al. The antitumor activity of the fungicide ciclopirox. Int. J. Cancer. 127(10), 2467-2477 (2010).
101. Kim Y, Alpmann P, Blaum-Feder S et al. In vivo efficacy of griseofulvin against multiple myeloma. Leuk. Res. 35(8), 1070-1073 (2011).
102. Lee SJ, Jin Y, Yoon HY et al. Ciclopirox protects mitochondria from hydrogen peroxide toxicity. Br. J. Pharmacol. 145(4), 469-476 (2005). (Pubitemid 40966276)
103. Hoque M, Hanauske-Abel HM, Palumbo P et al. Inhibition of HIV-1 gene expression by Ciclopirox and Deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A. Retrovirology 6, 90 (2009).
104. World malaria report 2011. www.who.int/malaria/world-malaria- report-2011/WMR2011-noprofiles- lowres.pdf
105. First WHO report on neglected tropical diseases: "Working to overcome the global impact of neglected tropical diseases." http://whqlibdoc.who.int/hq/2010/ WHO-HTM-NTD-2-eng.pdf
106. TDR (Research and Training in Tropical Diseases) annual report. http://apps.who.int/tdr/svc/publications/ about-tdr/annual-reports/tdr-report09
107. Discovery of Aspergillus as a human pathogen. www.antimicrobe.org/ history/Aspergillus-Human%20Pathogen.pdf